ReviewJournal of clinical microbiology2018
Impact of 21st Century Cures Act on Breakpoints and Commercial Antimicrobial Susceptibility Test Systems: Progress and Pitfalls.
Review in Journal of clinical microbiology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Inference of ceftobiprole susceptibility through surrogate testing of ceftaroline.Journal of clinical microbiology · 2026Article
- Navigating and Advancing Market Access for In Vitro Diagnostics: Understanding the Roles of Key Stakeholders and Policy.Open forum infectious diseases · 2025Article
- Evaluation of MicroScan and VITEK 2 systems for susceptibility testing of Enterobacterales with updated breakpoints.Journal of clinical microbiology · 2025Article
- Major updates to FDA-recognized Clinical and Laboratory Standards Institute breakpoints are a win for the fight against antimicrobial resistance.Journal of clinical microbiology · 2025Article
- Prevalence and antimicrobial drug resistance of gram-negative bacteria in dairy feed and water: a One Health concern.Frontiers in veterinary science · 2025Article
- Contemporary Considerations for Establishing Reference Methods for Antibacterial Susceptibility Testing.Journal of clinical microbiology · 2023Review
- Evaluation of Piperacillin-Tazobactam Testing againstJournal of clinical microbiology · 2023Article
- Microfluidic nanodevices for drug sensing and screening applications.Biosensors & bioelectronics · 2023Article
- Clinical challenges treatingJAC-antimicrobial resistance · 2022Review
- Stop Waiting for Tomorrow: Disk Diffusion Performed on Early Growth Is an Accurate Method for Antimicrobial Susceptibility Testing with Reduced Turnaround Time.Journal of clinical microbiology · 2022Article
- Raising the Bar: Improving Antimicrobial Resistance Detection by Clinical Laboratories by Ensuring Use of Current Breakpoints.Open forum infectious diseases · 2022Article
- Needs assessment for novel Gram-negative antibiotics in US hospitals: a retrospective cohort study.The Lancet. Infectious diseases · 2020Article
- New strategies and structural considerations in development of therapeutics for carbapenem-resistant Enterobacteriaceae.Translational research : the journal of laboratory and clinical medicine · 2020Review
- Article
- Bringing Antimicrobial Susceptibility Testing for New Drugs into the Clinical Laboratory: Removing Obstacles in Our Fight against Multidrug-Resistant Pathogens.Journal of clinical microbiology · 2019Article
- Understanding and Addressing CLSI Breakpoint Revisions: a Primer for Clinical Laboratories.Journal of clinical microbiology · 2019Review
- Evaluation of the MicroScan Colistin Well and Gradient Diffusion Strips for Colistin Susceptibility Testing inJournal of clinical microbiology · 2019Article
- Transmission of Mobile Colistin Resistance (mcr-1) by Duodenoscope.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2019Article
- Editorial: Beyond Antimicrobials: Non-traditional Approaches to Combating Multidrug-Resistant Bacteria.Frontiers in cellular and infection microbiology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antimicrobial resistance is the most pressing medical challenge of the past decade. At the front line are clinical laboratories, which are responsible for accurately reporting antimicrobial susceptibility test (AST) results to clinicians and public health authorities. The ability of the laboratory to detect resistance has been hampered by several factors. In 2016, the 21st Century Cures Act was signed into law, marking an important step toward resolving many regulatory dilemmas that hampered development and updates to commercial AST systems (cASTs). We describe the pathway and history of U.S. regulation of cASTs and outline both the rewards and unmet needs possible from the 21st Century Cures Act.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.